Gilead Sciences Inc (NASDAQ:GILD): Institutional Investor Sentiment Down to 0.92

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

Sentiment for Gilead Sciences Inc (NASDAQ:GILD)

Gilead Sciences Inc (NASDAQ:GILD) institutional sentiment decreased to 0.92 in 2019 Q2. Its down -0.10, from 1.02 in 2019Q1. The ratio turned negative, as 464 investment managers increased or opened new stock positions, while 503 sold and reduced stock positions in Gilead Sciences Inc. The investment managers in our partner’s database now possess: 960.10 million shares, down from 961.76 million shares in 2019Q1. Also, the number of investment managers holding Gilead Sciences Inc in their top 10 stock positions increased from 26 to 27 for an increase of 1. Sold All: 55 Reduced: 448 Increased: 357 New Position: 107.

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company has market cap of $85.33 billion. The companyÂ’s products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It has a 14.39 P/E ratio. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B.

The stock increased 0.05% or $0.03 during the last trading session, reaching $66.39. About 3.05 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 14.15% since September 13, 2018 and is downtrending. It has underperformed by 14.15% the S&P500.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on October, 24. They expect $1.72 earnings per share, up 1.18 % or $0.02 from last year’s $1.7 per share. GILD’s profit will be $2.21B for 9.65 P/E if the $1.72 EPS becomes a reality. After $1.72 actual earnings per share reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Krensavage Asset Management Llc holds 12.09% of its portfolio in Gilead Sciences, Inc. for 551,237 shares. Healthcare Value Capital Llc owns 70,000 shares or 8.87% of their US portfolio. Moreover, Holowesko Partners Ltd. has 6.33% invested in the company for 1.14 million shares. The Massachusetts-based Tekla Capital Management Llc has invested 5.06% in the stock. Sector Gamma As, a Norway-based fund reported 445,056 shares.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

Ratings analysis reveals 71% of Gilead Sciences’s analysts are positive. Out of 7 Wall Street analysts rating Gilead Sciences, 5 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $6700 while the high is $88. The stock’s average target of $78 is 17.49% above today’s ($66.39) share price. GILD was included in 17 notes of analysts from March 14, 2019. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Strong Buy” rating by Raymond James on Wednesday, July 31. The rating was maintained by Piper Jaffray on Sunday, March 17 with “Hold”. The company was maintained on Friday, March 15 by Mizuho. As per Tuesday, March 19, the company rating was maintained by Oppenheimer. The firm has “Neutral” rating given on Wednesday, July 31 by Credit Suisse. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Friday, June 21 by Mizuho. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Wednesday, April 10 by UBS. The firm has “Buy” rating given on Thursday, March 14 by BMO Capital Markets.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: which released: “Notable Tuesday Option Activity: GILD, EVRI, PLT – Nasdaq” on August 06, 2019, also with their article: “Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for September 12, 2019 – Nasdaq” published on September 11, 2019, published: “Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know – Nasdaq” on August 30, 2019. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: and their article: “What Should You Know About Gilead Sciences, Inc.’s (NASDAQ:GILD) Future? – Yahoo Finance” published on July 02, 2019 as well as‘s news article titled: “Sum Up The Parts: ESGL Could Be Worth $35 – Nasdaq” with publication date: September 09, 2019.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.